- Home
- CAC vs EYPT Comparison
CAC vs EYPT Comparison
Compare CAC & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- EYPT
- Stock Information
- Founded
- CAC 1875
- EYPT 1987
- Country
- CAC United States
- EYPT United States
- Employees
- CAC N/A
- EYPT N/A
- Industry
- CAC Major Banks
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- CAC Finance
- EYPT Industrials
- Exchange
- CAC Nasdaq
- EYPT Nasdaq
- Market Cap
- CAC N/A
- EYPT 489.4M
- IPO Year
- CAC 1997
- EYPT 2005
- Fundamental
- Price
- CAC $45.25
- EYPT $7.69
- Analyst Decision
- CAC Hold
- EYPT Strong Buy
- Analyst Count
- CAC 3
- EYPT 8
- Target Price
- CAC $48.33
- EYPT $25.71
- AVG Volume (30 Days)
- CAC 87.0K
- EYPT 665.0K
- Earning Date
- CAC 01-28-2025
- EYPT 03-06-2025
- Dividend Yield
- CAC 3.74%
- EYPT N/A
- EPS Growth
- CAC 21.89
- EYPT N/A
- EPS
- CAC 3.62
- EYPT N/A
- Revenue
- CAC $177,396,000.00
- EYPT $45,713,000.00
- Revenue This Year
- CAC N/A
- EYPT N/A
- Revenue Next Year
- CAC $10.12
- EYPT N/A
- P/E Ratio
- CAC $12.27
- EYPT N/A
- Revenue Growth
- CAC 10.05
- EYPT 7.50
- 52 Week Low
- CAC $28.62
- EYPT $6.90
- 52 Week High
- CAC $50.07
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- CAC 51.55
- EYPT 41.66
- Support Level
- CAC $45.00
- EYPT $7.58
- Resistance Level
- CAC $46.49
- EYPT $8.16
- Average True Range (ATR)
- CAC 1.20
- EYPT 0.55
- MACD
- CAC 0.24
- EYPT -0.07
- Stochastic Oscillator
- CAC 48.77
- EYPT 3.06
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.